QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
NASDAQ:CTIC

CTI BioPharma - CTIC Stock Forecast, Price & News

$5.41
-0.26 (-4.59%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.37
$5.72
50-Day Range
$5.16
$7.43
52-Week Range
$1.43
$7.80
Volume
6.75 million shs
Average Volume
4.73 million shs
Market Capitalization
$618.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.33

CTI BioPharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
91.0% Upside
$10.33 Price Target
Short Interest
Healthy
14.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.51mentions of CTI BioPharma in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$45.73 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.78) to $0.39 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

559th out of 1,124 stocks

Pharmaceutical Preparations Industry

279th out of 555 stocks

CTIC stock logo

About CTI BioPharma (NASDAQ:CTIC) Stock

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

CTI BioPharma Price Performance

CTIC opened at $5.67 on Tuesday. The stock's 50 day simple moving average is $6.21 and its 200 day simple moving average is $4.85. The firm has a market cap of $648.56 million, a price-to-earnings ratio of -4.65 and a beta of 0.86. CTI BioPharma has a 1 year low of $1.43 and a 1 year high of $7.80.

CTI BioPharma (NASDAQ:CTIC - Get Rating) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). During the same period in the previous year, the company posted ($0.21) EPS. As a group, sell-side analysts anticipate that CTI BioPharma will post -0.78 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on CTIC shares. Cowen initiated coverage on CTI BioPharma in a research note on Thursday, July 7th. They set an "outperform" rating and a $10.00 price target for the company. Cowen began coverage on CTI BioPharma in a research report on Thursday, July 7th. They issued an "outperform" rating and a $10.00 target price for the company. Needham & Company LLC increased their price target on shares of CTI BioPharma from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Tuesday, August 9th. Finally, JMP Securities lifted their price target on shares of CTI BioPharma from $6.00 to $9.00 and gave the stock a "market outperform" rating in a research note on Tuesday, August 9th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $10.33.

Insider Buying and Selling at CTI BioPharma

In related news, Director Michael A. Metzger sold 91,500 shares of the firm's stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $6.08, for a total value of $556,320.00. Following the sale, the director now directly owns 20,121 shares of the company's stock, valued at $122,335.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other CTI BioPharma news, CFO David Kirske sold 10,000 shares of the company's stock in a transaction on Tuesday, June 14th. The shares were sold at an average price of $5.50, for a total value of $55,000.00. Following the completion of the transaction, the chief financial officer now directly owns 7,397 shares in the company, valued at approximately $40,683.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael A. Metzger sold 91,500 shares of the firm's stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $6.08, for a total transaction of $556,320.00. Following the completion of the sale, the director now directly owns 20,121 shares of the company's stock, valued at $122,335.68. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 7,473,187 shares of company stock worth $45,729,572. 10.20% of the stock is currently owned by company insiders.

Receive CTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CTIC Stock News Headlines

CTI BioPharma: Q2 Earnings Insights
CTI BioPharma: One Trick Pony Ready To Perform
Why CTI BioPharma Stock Blasted 18% Higher Today
Why CTI Biopharma Stock Is Surging Today
CTI BioPharma Q1 2022 Earnings Preview
Keep an eye on the momentum at Cti Biopharma
See More Headlines
Receive CTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CTIC Company Calendar

Last Earnings
8/08/2022
Today
8/16/2022
Next Earnings (Estimated)
11/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTIC
Previous Symbol
NASDAQ:CTICD
Employees
22
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$10.33
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+91.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-97,910,000.00
Pretax Margin
-826.01%

Debt

Sales & Book Value

Annual Sales
$3.35 million
Book Value
$0.04 per share

Miscellaneous

Free Float
102,718,000
Market Cap
$618.82 million
Optionable
Optionable
Beta
0.86

Social Links


Key Executives

  • Dr. Adam R. Craig M.B.A. (Age 56)
    M.D., Ph.D., Pres, CEO, Interim Chief Medical Officer & Director
    Comp: $1.02M
  • Mr. David H. Kirske (Age 68)
    Exec. VP, CFO & Sec.
    Comp: $542.34k
  • Mr. Bruce J. Seeley (Age 58)
    Exec. VP & COO
    Comp: $642.36k
  • Mr. Ed Bell
    Sr. Director of Investor Relations
  • Mr. James K. Fong (Age 60)
    Sr. VP & Chief Commercial Officer
  • Mr. Bruce K. Bennett Jr. (Age 70)
    Sr. VP Global Pharmaceutical Operations
  • Mr. John Volpone
    Sr. VP of Strategic Operations
  • Dr. Jennifer A. Smith
    Sr. VP of Biometrics













CTIC Stock - Frequently Asked Questions

Should I buy or sell CTI BioPharma stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CTIC shares.
View CTIC analyst ratings
or view top-rated stocks.

What is CTI BioPharma's stock price forecast for 2022?

6 analysts have issued 12 month price targets for CTI BioPharma's shares. Their CTIC share price forecasts range from $9.00 to $12.00. On average, they expect the company's stock price to reach $10.33 in the next twelve months. This suggests a possible upside of 91.0% from the stock's current price.
View analysts price targets for CTIC
or view top-rated stocks among Wall Street analysts.

How have CTIC shares performed in 2022?

CTI BioPharma's stock was trading at $2.48 at the beginning of 2022. Since then, CTIC stock has increased by 118.1% and is now trading at $5.41.
View the best growth stocks for 2022 here
.

When is CTI BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our CTIC earnings forecast
.

How were CTI BioPharma's earnings last quarter?

CTI BioPharma Corp. (NASDAQ:CTIC) released its earnings results on Monday, August, 8th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.01. During the same quarter last year, the business earned ($0.21) earnings per share.

When did CTI BioPharma's stock split?

CTI BioPharma's stock reverse split on the morning of Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is James A. Bianco's approval rating as CTI BioPharma's CEO?

8 employees have rated CTI BioPharma Chief Executive Officer James A. Bianco on Glassdoor.com. James A. Bianco has an approval rating of 27% among the company's employees. This puts James A. Bianco in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of CTI BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Vaxart (VXRT), Dynavax Technologies (DVAX) and Trevena (TRVN).

What is CTI BioPharma's stock symbol?

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

Who are CTI BioPharma's major shareholders?

CTI BioPharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include State Street Corp (8.61%), Millennium Management LLC (2.77%), Silverarc Capital Management LLC (1.27%), Northern Trust Corp (0.66%), Point72 Asset Management L.P. (0.59%) and Knott David M Jr (0.50%). Insiders that own company stock include Adam R Craig, Bvf Partners L P/Il, David Kirske, Michael A Metzger and Orbimed Advisors Llc.
View institutional ownership trends
.

How do I buy shares of CTI BioPharma?

Shares of CTIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CTI BioPharma's stock price today?

One share of CTIC stock can currently be purchased for approximately $5.41.

How much money does CTI BioPharma make?

CTI BioPharma (NASDAQ:CTIC) has a market capitalization of $618.82 million and generates $3.35 million in revenue each year. The biopharmaceutical company earns $-97,910,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis.

When was CTI BioPharma founded?

CTI BioPharma was founded in 1992.

How can I contact CTI BioPharma?

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The official website for the company is www.ctibiopharma.com. The biopharmaceutical company can be reached via phone at (206) 282-7100, via email at invest@ctibiopharma.com, or via fax at 206-284-6206.

This page (NASDAQ:CTIC) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.